Heininger U, Stehr K, Christenson P, Cherry J D
Klinik mit Poliklinik für Kinder und Jugendliche der Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
Clin Infect Dis. 1999 Mar;28(3):602-4. doi: 10.1086/515154.
A subanalysis of a recent cohort efficacy trial of a pertussis vaccine was performed to determine its efficacy against cough illnesses due to Bordetella parapertussis infections. Infants received four doses of either the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis (DTaP) vaccine or the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis (DTP) vaccine at 3, 4.5, 6, and 15-18 months of age; controls received three doses of diphtheria and tetanus toxoids (DT) vaccine only. All subjects were prospectively followed for cough illnesses of > or = 7 days' duration; cases of B. parapertussis infection were confirmed by positive culture, household contact, or serology. Seventy-six cough illnesses due to B. parapertussis were identified; 24 occurred in 929 DTaP recipients, 37 in 937 DTP recipients, and 15 in 321 DT recipients, resulting in an efficacy of 50% for DTaP vaccine (95% CI [confidence interval], 5% to 74%) and 21% for DTP vaccine (95% CI, -45% to 56%). The data in the present analysis suggest that the Lederle/Takeda DTaP vaccine but not the Lederle whole-cell component DTP vaccine has efficacy against B. parapertussis infection.
对近期一项百日咳疫苗队列疗效试验进行了亚组分析，以确定其对副百日咳博德特氏菌感染所致咳嗽疾病的疗效。婴儿在3、4.5、6和15 - 18月龄时接受四剂Lederle/武田无细胞百日咳成分白喉破伤风类毒素和百日咳（DTaP）疫苗或Lederle全细胞成分白喉破伤风类毒素和百日咳（DTP）疫苗；对照组仅接受三剂白喉破伤风类毒素（DT）疫苗。对所有受试者进行前瞻性随访，观察持续时间≥7天的咳嗽疾病；副百日咳博德特氏菌感染病例通过阳性培养、家庭接触或血清学确诊。共识别出76例由副百日咳博德特氏菌引起的咳嗽疾病；929名DTaP疫苗接种者中有24例，937名DTP疫苗接种者中有37例，321名DT疫苗接种者中有15例，DTaP疫苗的疗效为50%（95%置信区间[CI]，5%至74%），DTP疫苗的疗效为21%（95%CI，-45%至56%）。本分析中的数据表明，Lederle/武田DTaP疫苗对副百日咳博德特氏菌感染有效，但Lederle全细胞成分DTP疫苗无效。
